‘Game-changing’ artificial pancreas app now available on iOS in the UK

The product images are for illustrative purposes only. // mylife and YpsoPump are registered trademarks of Ypsomed AG in several countries. // CamAPS is a registered trademark of CamDiab Ltd. // Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries. // The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. // The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc., and any use of such marks by Ypsomed is under license. // Other trademarks are the property of their respective owners. // iPhone and Apple are trademarks of Apple Inc., registered in the US and other countries and regions.

mylife CamAPS FX app launches on iOS in the UK, empowering easier diabetes management

A cutting-edge, adaptive hybrid closed-loop app designed to simplify life for people with type 1 diabetes is now available on iOS smartphones across the UK.

CamDiab, in collaboration with Ypsomed, has officially launched the iOS version of the mylife CamAPS FX app in the UK, marking the first time users in England, Scotland, Wales and Northern Ireland can easily and discreetly manage their mylife Loop directly from their iPhones.

This is the next wave of the international rollout of the mylife CamAPS FX app on iOS, following its pilot launch in Sweden on March 24, 2025.

Alongside the UK, this phase will also see the iOS version of the mylife CamAPS FX app go live in the Republic of Ireland, Germany, Denmark, Austria, Norway, Finland and Luxembourg.

Professor Roman Hovorka, CamAPS FX creator and Professor of Metabolic Technology at the Institute of Metabolic Science and Department of Paediatrics at the University of Cambridge, said: “We are thrilled to bring the mylife CamAPS FX app to iOS users across the UK.

“This launch represents a significant step forward in making advanced, adaptive diabetes technology more accessible and convenient.”

He added: “By enabling people with type 1 diabetes to discreetly and effectively manage their condition directly from their iPhones, we are delivering on our commitment to simplify diabetes care and improve quality of life.

“Our collaboration with Ypsomed continues to empower users through cutting-edge solutions that blend seamlessly into everyday life.”

The adaptive mylife CamAPS FX algorithm runs on the personal smartphone and is approved for people with type 1 diabetes from one year of age, including the use in pregnancy, depending on the sensor used for continuous glucose monitoring.

Professor Helen Murphy, Professor of Medicine (Diabetes and Antenatal Care) at the University of East Anglia and Professor of Women's Health at Kings College London, said: “CamAPS FX is changing the landscape of type 1 diabetes management before, during and after pregnancy.

“The iOS rollout means that even more women can benefit from this life-changing technology, which improves maternal glucose levels, reduces birth complications and will save babies lives.”

She added: “For more information on accessing NHS funding for CamAPS FX and Saving Babies Lives see SBLCB Version 3.2 element six.”

The mylife CamAPS FX algorithm is combined with the mylife YpsoPump insulin pump and with a sensor for continuous glucose monitoring, either with the FreeStyle Libre 3 or the FreeStyle Libre 3 Plus from Abbott or the Dexcom G6 from Dexcom. The automated insulin delivery (AID) system mylife Loop is marketed in most European countries, Canada, Australia and New Zealand.

Professor Partha Kar, Type 1 Diabetes and Tech lead for NHS England and GIRFT, said: “The launch of CamAPS FX on iOS is an important step in expanding access to safe, evidence-based digital health solutions for people living with type 1 diabetes.

 “It also reflects the UK’s position as a global leader in driving inclusive, tech-enabled healthcare through strong academic, clinical, and industry collaboration.”

The rollout of the mylife CamAPS FX app on iOS will continue across Europe, Australia and New Zealand over the next few months.

CamDiab Ltd is a digital health company focused on the design, development, and commercialisation of its world leading, interoperable CamAPS FX closed loop app.

The CamAPS FX is designed to use adaptive, self-learning control algorithm, linked to a compatible continuous glucose monitoring device and a compatible insulin pump, to autonomously compute and direct insulin delivery to maintain tight glycaemic control.

Ypsomed is the leading developer and manufacturer of injection and infusion systems for self-medication and a renowned diabetes specialist. Ypsomed presents and markets its product portfolios under the umbrella brand mylife Diabetescare directly to patients, pharmacies and hospitals as well as under Ypsomed Delivery Systems in business-to-business operations with pharmaceutical companies.

For further information, visit www.camdiab.com or follow CamDiab Ltd and its products on Facebook, LinkedIn, and Twitter @CamAPS_FX.